中国团队首次在Nature子刊发布医疗AI标准，未来医生MedGPT摘得全球桂冠

Core Viewpoint - The article highlights the introduction of the Clinical Safety-Effectiveness Dual-Track Benchmark (CSEDB), a standardized framework for evaluating the real clinical capabilities of medical AI models, developed by a collaboration of Chinese AI medical company "Future Doctor" and 32 leading clinical experts from top medical institutions in China [1][4][14]. Group 1: CSEDB Framework - CSEDB establishes a systematic framework for assessing the clinical capabilities of medical AI, focusing on both safety and effectiveness separately [4][15]. - The framework includes a risk-weighting mechanism, assigning weights from 1 to 5 based on the potential clinical risks associated with each evaluation metric [16][17]. - CSEDB covers 2069 open-ended questions across 26 clinical specialties, simulating real clinical scenarios and emphasizing the model's performance in continuous decision-making [20][22]. Group 2: MedGPT Performance - MedGPT, developed by Future Doctor, ranked first in overall scores, safety, and effectiveness among major global models evaluated under CSEDB [27]. - Notably, MedGPT is the only model that scored higher in safety than in effectiveness, indicating a significant advantage in clinical safety [28]. - The model employs a dual-system architecture, with a "fast system" for routine scenarios and a "slow system" for complex cases, ensuring a balance between speed and thoroughness in clinical decision-making [31][36]. Group 3: Industry Implications - The research signals a shift in the medical AI industry from merely demonstrating capabilities to defining responsibilities and ensuring safety in clinical applications [8][9]. - The competitive landscape in medical AI is intensifying, with major players like Google and OpenAI investing heavily in this sector [9]. - The article emphasizes that the long-term clinical value of medical AI will be more critical than short-term technological advantages, framing the competition as a marathon rather than a sprint [54][56].